Glyscend taps CEO to lead oral obesity, type 2 diabetes candidate; Ex-Travecta chief bounces back after company shutdown

Sapan Shah

As a new wave of type 2 diabetes and obesity drugs takes the industry by storm, Glyscend Therapeutics has tapped a new CEO to lead the charge for its candidate designed to mimic metabolic surgery.

Sapan Shah is taking the driver’s seat at…
Click here to view original post